REPL vs UNH

Replimune (REPL) now faces a significantly heightened risk profile following the FDA's second Complete Response Letter (CRL) for RP1 in anti-PD-1-failed melanoma. This crucial setback invalidates the primary near-term catalyst and severely delays commercialization, pushing out any potential 10x growth within the 3-5 year timeframe. The market has reacted with a ~60% stock decline, widespread analy...

UnitedHealth Group (UNH) remains a robust, high-quality mega-cap in the mature and highly regulated healthcare sector. Q1 2026 adjusted EPS of $7.23, a recent dividend increase to $2.32, and some analyst upgrades (e.g., Truist to $440, Goldman Sachs Conviction Buy) reflect solid operational performance and financial strength. However, these are characteristics of a stable compounder, not a company...